CSI Market
Sign In | Register

Intellipharmaceutics International Inc (IPCIF) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IPCIF Annual Cash Flow →
Examining cash flow movements between Intellipharmaceutics International Inc and May 31 2023 reveals how Nov 30 2022 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Nov 30 2022)
12 Months 		0 (Aug 31 2023) 0 (May 31 2023)
Operating Activities
Income-2.89
Depreciation & amortization0.21
Amortization of Other Assets0.00
Accretion Expense0.07
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventory Write-down0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.04
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.02
Deferred Compensation Arrangement With Individual Compensation Expense-
Debt Instrument Increase Accrued Interest-
Investment Tax Credits Write Down-
Deferred Income Tax Recovery-
Write Down Of Investment Tax Credits-
Non Cash Lease Expense-
Prepaid Expenses Sundry And Other Assets-
Impairment Of Intangible Assets Excluding Goodwill-
Increase Decrease In Investment Tax Credits-
Income taxes-0.01
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.34
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.08
Other Working Capital0.00
Other Noncash Expense0.01
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-1.39
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.50
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.50
Financing Activities
Short-term debt Net0.20
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Warrants Exercised-
Offering Costs-
Noninterest Expense Offering Cost-
Proceeds From Issuance Of Shares And Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.20
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.89
Total Cash Flow-0.69
4 historic quarters locked

Sign in to unlock the full Intellipharmaceutics International Inc cash flow history.

Sign In Create Free Account

About Intellipharmaceutics International Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001654954-23-008028

Figures are derived from filed reports and may be restated. Historical data is subject to revision.